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Abstract 
Background: Nodular melanoma (NM) accounts for most thick melanomas and because of their frequent associa-
tion with ulceration, fast growth rate and high mitotic rate, contribute substantially to melanoma-related mortality. 
In a multicentric series of 214 primary melanomas including 96 NM and 118 superficial spreading melanoma (SSM), 
histopathological features were examined with the aim to identify clinicopathological predictors of recurrence.
Methods: All consecutive cases of histopathologically diagnosed primary invasive SSM and NM during the period 
2005–2010, were retrieved from the 12 participating Italian Melanoma Intergroup (IMI) centers. Each center provided 
clinico-pathological data such as gender, age at diagnosis, anatomical site, histopathological conventional param-
eters, date of excision and first melanoma recurrence.
Results: Results showed that NM subtype was significantly associated with Breslow thickness (BT) at multivariate 
analysis: [BT 1.01–2 mm (OR 7.22; 95% CI 2.73–19.05), BT 2.01–4 mm (OR 7.04; 95% CI 2.54–19.56), and BT > 4 mm (OR 
51.78; 95% CI 5.65–474.86) (p < 0.0001)]. Furthermore, mitotic rate (MR) was significantly correlated with NM histotype: 
[(MR 3–5 mitoses/mm2 (OR 2.62; 95% CI 1.01–6.83) and MR > 5 mitoses/mm2 (OR 4.87; 95% CI 1.77–13.40) (p = 0.002)]. 
The risk of recurrence was not significantly associated with NM histotype while BT [BT 1.01–2.00 mm (HR 1.55; 95% 
CI 0.51–4.71), BT 2.01–4.00 mm (HR 2.42; 95% CI 0.89–6.54), BT > 4.00 mm. (HR 3.13; 95% CI 0.95–10.28) (p = 0.05)], 
mitotic rate [MR > 2 mitoses/mm2 (HR 2.34; 95% CI, 1.11–4.97) (p = 0.03)] and the positivity of lymph node sentinel 
biopsy (SNLB) (HR 2.60; 95% CI 1.19–5.68) (p = 0.007) were significantly associated with an increased risk of recurrence 
at multivariate analysis.
Conclusions: We found that NM subtype was significantly associated with higher BT and MR but it was not a prog-
nostic factor since it did not significantly correlate with melanoma recurrence rate. Conversely, increased BT and MR 
as well as SNLB positivity were significantly associated with a higher risk of melanoma recurrence.
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Background
The incidence of melanoma is increasing worldwide with 
highest rates in northern Europe, United States and Aus-
tralia [1]. The most commonly prognostic parameters in 
the recent AJCC/UICC staging model are breslow thick-
ness (BT), ulceration and microscopic satellite while 
mitotic rate (MR) is an additional attribute that may be 
used in decision-making [2]. Nodular melanoma (NM) 
presenting with vertical growth phase without evidence 
of an initial radial growth phase, grows faster than mel-
anomas associated with a radial growth phase such as 
superficial spreading melanoma (SSM) and lentigo malig-
nant melanoma (LMM) [3].
According to the new taxonomy framework, NM may 
occur in sun-exposed skin without or with low cumula-
tive sun-induced damage (low-CSD) or develop on skin 
with cumulative sun-induced damage (high-CSD) [4]. 
NM account for most thick melanomas and because of 
their frequent association with ulceration, fast growth 
and high mitotic rate, substantially contribute to mela-
noma-related mortality [3, 5–7].
LMM and SSM have been found to have a better prog-
nosis than NM, however, when comparing for melanoma 
thickness, a significant difference between the subtypes 
was not found [8]. SSM and NM are believed to represent 
sequential phases of linear progression from radial to 
vertical growth. Clinical, pathological and epidemiologic 
evidences suggest, however, that SSM and NM might be 
the result of independent pathways of tumor develop-
ment and underlying molecular differences between the 
two subtypes that may also contribute to the disparate 
outcomes.
The aims of the current study were to evaluate clini-
cal and histopathological features associated with NM 
and SSM and to identify independent clinicopathological 
prognostic factors in a multicentre series of 214 primary 
melanomas including 96 NM and 118 SSM.
Methods
The study series included only a limited fraction of the 
consecutive cases of histopathologically diagnosed pri-
mary invasive SSM and NM, presented with the combi-
nation of clinical and dermoscopic images and complete 
clinical history, observed during the period 2005–2010, 
in 12 Italian Melanoma Intergroup (IMI) centers. In 
order to guarantee sample homogeneity, only SSM and 
NM cases in patients with at least 5  years of follow-up, 
by the end of 2015 were included into the study. Each 
center provided clinical and pathological data such as 
gender, age at diagnosis, melanoma site, date of excision, 
pathological conventional parameters and date of first 
melanoma recurrence. By the beginning of January 2016, 
all information from the 12 centers was merged into a 
database at the Cancer Epidemiology Unit (R.T.) of the 
Centro di Riferimento Oncologico, Aviano (Italy), with a 
new identification link to the patient information on clin-
ical features and histopathological diagnosis.
Statistical analyses
Statistical analysis was performed by means of SAS sta-
tistical software 9.1 (SAS Institute Inc., Cary, NC, USA). 
Odds ratios (ORs) and corresponding 95% confidence 
intervals (CIs) were computed by unconditioned logis-
tic regression to evaluate differences in the distribution 
of histopathological features of NM vs SSM. The signifi-
cance of OR (β parameter) was tested through Wald Chi 
square. Statistically significant variables in the univariate 
analysis were included in the multivariate model. Tests 
for trend were based on the likelihood-ratio test between 
the models with and without a linear term for each vari-
able of interest. The probability of recurrence was com-
puted from the date of melanoma diagnosis to the date 
of first relapse or last follow-up. The curves of probabil-
ity of recurrence were conducted by the Kaplan–Meier 
method and the differences were assessed with the log-
rank test [9]. In addition, the differences were also tested 
in univariate and multivariate analyses using the Cox 
proportional hazards model to compute the hazard ratio 
(HR) and corresponding 95% confidence interval (CI) 
[10]. The significance of HR (β parameter) was tested 
through Wald Chi square. All results were considered 
statistically significant for values of p ≤ 0.05 (two-tailed 
test).
Results
Of 214 primary cutaneous melanoma, 96 were NM and 
118 were SSM. The study included 214 patients (118 
men, 96 women) with a median age of 61  years (range: 
21–96 years) for patients with NM and 57 years (range: 
16–92) for patients with SSM. The sites of primary mel-
anoma included head and neck (n = 17); limb (n = 84); 
and trunk (n = 113). We observed no differences between 
NM and SSM with regard to the distribution by sex, age, 
sites of melanomas, previous personal or family history 
of melanoma (data not shown).
Table 1 shows the univariate and multivariate analysis 
(OR) of main histopathological features of NM vs SSM. 
Multivariate analysis showed that BT was significantly 
associated with NM subtype: [BT 1.01–2 mm (OR 7.22; 
95% CI 2.73–19.05), BT 2.01–4  mm (OR 7.04; 95% CI 
2.54–19.56), and BT  >  4  mm (OR 51.78; 95% CI 5.65–
474.86) (p < 0.0001)] (Table 1). Furthermore mitotic rate 
(MR) was significantly correlated with NM histotype: 
[(MR 3–5 mitoses/mm2 (OR 2.62; 95% CI 1.01–6.83) 
and MR > 5 mitoses/mm2 (OR 4.87; 95% CI 1.77–13.40) 
(p = 0.002)] (Table 1).
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Table 2 shows the univariate and multivariate analysis 
of recurrence (HR) of some histopathological features 
in patients with NM and SSM. Multivariate analysis 
showed that BT [BT 1.01–2.00  mm (HR 1.55; 95% CI 
0.51–4.71), BT 2.01–4.00  mm (HR 2.42; 95% CI, 0.89–
6.54), BT  >  4.00  mm. (HR 3.13; 95% CI 0.95–10.28) 
(p = 0.05)], MR > 2 mitoses/mm2 (HR 2.34; 95% CI 1.11–
4.97) (p = 0.03) and the positivity of sentinel lymph node 
biopsy (SNLB) (HR 2.60; 95% CI 1.19–5.68) (p = 0.007) 
were significantly associated with an increased risk of 
recurrence (Table 2).
By contrast, the risk of progression was not signifi-
cantly associated with NM histotype (Table 2).
The probability of recurrence according to BT and 
MR are reported in Fig.  1; at 5  years, the percentage of 
patients recurrence free were 45% (95% CI 23–65), 56% 
(95% CI 43–67), 83% (95% CI 68–92), and 92% (95% CI 
83–96) for patients with BT > 4.00 mm, 2.01–4.00 mm, 
1.01–2.00  mm, and  ≤  1  mm, respectively. In addition, 
the percentage of patients recurrence free were 55% (95% 
CI 44–65), and 89% (95% CI 81–94), for MR > 2, and ≤ 2 
mitoses/mm2, respectively.
Discussion
The NM subtype accounts for a large amount of thick 
melanomas, representing from 40 to 65% of all > 2 mm-
thick melanomas [6, 11, 12]. In line with previous reports 
[6, 11–13], present results indicate that the NM subtype 
is significantly associated with higher BT and MR values 
at multivariate analysis. Furthermore, our results support 
Table 1 Univariate and  multivariate analysis (OR) of  some histopathological features of  nodular melanoma (NM) ver-
sus superficial spreading melanomas (SSMs)
a Odds Ratio and 95% confidence interval (CI)
b Reference category
c Model including all significant terms in the univariate analysis










 ≤ 1.00 9 (9.4) 72 (61.0) 1b 1b
 1.01–2.00 24 (25.0) 22 (18.6) 8.73 (3.54–21.52) 7.22 (2.73–19.05)
 2.01–4.00 44 (45.8) 22 (16.6) 16.00 (6.76–37.87) 7.04 (2.54–19.56)
 > 4.00 19 (19.8) 2 (1.7) 76.00 (15.14–381.51) 51.78 (5.65–474.86)
 χ2 1 trend: p value p < 0.0001 p < 0.0001
Ulceration
 Absent 46 (47.9) 96 (81.4) 1b 1b
 Present 43 (44.8) 18 (15.2) 4.98 (2.59–9.57) 1.56 (0.67–3.62)
 Unknown 7 (7.3) 4 (3.4)
 χ2 1: p value p < 0.0001 p = 0.3066
Regression
 Absent 65 (67.7) 67 (56.8) 1b 1b
 Present 24 (25.0) 46 (39.0) 0.54 (0.30–0.98) 0.55 (0.25–1.22)
 Unknown 7 (7.3) 5 (4.2)
 χ2 1: p value p = 0.0428 p = 0.1393
Mitoses (n/mm2)
 ≤ 2 31 (32.3) 86 (72.9) 1b 1b
 3–5 24 (25.0) 14 (11.9) 4.76 (2.19–10.34) 2.62 (1.01–6.83)
 > 5 35 (36.5) 11 (9.3) 8.83 (4.00–19.49) 4.87 (1.77–13.40)
 Unknown 6 (6.2) 7 (5.9)
 χ2 1 trend: p value p < 0.0001 p = 0.0015
TILd
 Absent 29 (30.2) 34 (28.8) 1b
 Brisk 14 (14.6) 27 (22.9) 0.61 (0.27–1.37)
 Non-Brisk 46 (47.9) 48 (40.7) 1.12 (0.59–2.13)
 Unknown 7 (7.3) 9 (7.6)
 χ2 1 trend: p value p = 0.6174
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previous observations that NM presents with higher MR 
values than SSM; indeed, the median number of mitoses 
reported for NM vs SSM was 2.5 and 1/mm2 respectively 
[13]. Different features of the two melanoma subtypes 
may derive from distinct genetic pathways and different 
origin [7, 14]. One could speculate that the hypothesized 
origin of NM from dermal stem cells and SSM from epi-
dermal stem cells [14] could explain behavioral differ-
ences between the two melanoma subtypes. In particular, 
the growth of NM much faster than that of SSM should be 
considered as a feature closely associated with higher BT 
and MR scores among NM lesions [3].
Table 2 Univariate and multivariate analysis of recurrence (HR) of some histopathological features of patients with nod-
ular melanoma (NM) and superficial spreading melanomas (SSMs)
a Hazard ratio and 95% confidence interval (CI)
b Reference category
c Model including all significant terms in the univariate analysis
d Tumor infiltrating lymphocytes
Recurrence Univariate Multivariatec
Yes (N. 53) No (N. 161) HR (95% CI)a HR (95% CI)a
Diagnosis
 SSMs 14 (26.4) 104 (64.6) 1b 1b
 NM 39 (73.6) 57 (35.4) 4.09 (2.22–7.53) 1.62 (0.77–3.39)
 χ2 1: p value p < 0.0001 p = 0.2016
Thickness (mm)
 ≤ 1 7 (13.2) 74 (46.0) 1b 1b
 1.01–2.00 7 (13.2) 39 (24.2) 2.07 (0.72–5.89) 1.55 (0.51–4.71)
 2.01–4.00 28 (52.8) 38 (23.6) 5.85 (2.55–13.41) 2.42 (0.89–6.54)
 > 4.00 11 (20.8) 10 (6.2) 7.45 (2.89–19.22) 3.13 (0.95–10.28)
 χ2 1 trend: p value p < 0.0001 p = 0.0456
Ulceration
 Absent 29 (54.7) 113 (70.2) 1b 1b
 Present 24 (45.3) 37 (23.0) 2.10 (1.22–3.61) 0.74 (0.40–1.39)
 Unknown – 11 (6.8)
 χ2 1: p value p = 0.0073 p = 0.3513
Regression
 Absent 37 (69.8) 95 (59.0) 12
 Present 16 (30.2) 54 (33.5) 0.81 (0.45–1.45)
 Unknown – 12 (7.5)
 χ2 1: p value p = 0.4687
Mitoses (n/mm2)
 ≤ 2 13 (24.5) 104 (64.6) 1b 1b
 > 2 37 (69.8) 47 (29.2) 4.75 (2.52–8.94) 2.34 (1.11–4.97)
 Unknown 3 (5.7) 10 (6.2)
 χ2 1: p value p < 0.0001 p = 0.0263
TILd
 Absent 21 (39.6) 42 (26.1) 1b
 Brisk 9 (17.0) 32 (19.9) 0.62 (0.29–1.36)
 Non-Brisk 22 (41.5) 72 (44.7) 0.64 (0.35–1.16)
 Unknown 1 (1.9) 15 (9.3)
 χ2 1 trend: p value p = 0.1527
Lymph nodes sentinel
 No suggest 15 (28.3) 81 (50.3) 1b 1b
 Yes-negative 16 (30.2) 66 (41.0) 1.14 (0.56–2.31) 0.77 (0.35–1.69)
 Yes-positive 22 (41.5) 14 (8.7) 5.24 (2.71–10.13) 2.60 (1.19–5.68)
 χ2 1 trend: p value p < 0.0001 p = 0.0073
Page 5 of 7Pizzichetta et al. J Transl Med  (2017) 15:227 
By multivariate analysis, ulceration and regression were 
not significantly more frequent in NM as compared with 
SSM. In agreement with our results, Warycha et al. [13] 
did not find any significant difference between NM and 
SSM regarding the presence of regression. In contrast 
with our findings, this study however reported a signifi-
cantly higher probability for NM to be found ulcerated 
[13].
No statistically significant difference was found in NM 
vs SSM in relation to tumor infiltrating lymphocytes 
(TILs) in the univariate analysis. This result is in contrast 
with that of other studies showing that patients with TILs 
more likely had nodular histology [15].
A limitation to our retrospective study was the selec-
tion bias and institutional variation in pathology assess-
ment that could have potentially influenced our results.
NM was more frequently diagnosed in older men 
(≥ 50 years), particularly on the lower limbs or head and 
neck regions [6]. Consistently with Warycha et  al. [13] 
study, we did not find any differences between NM and 
SSM regarding sex, age, and anatomical site (data not 
shown).
In agreement with prior reports [16–18], increas-
ing BT, MR with > 2 mitoses/mm2, and the positivity of 
SNLB were significantly associated with an increased 
risk of recurrence in all melanoma cases (regardless of 
the subtype, NM or SSM). However, MR can be associ-
ated with SNLB positivity as reported by Mandalà et al. 
[19], whose study found that MR > 1 mitoses/mm2 in pri-
mary cutaneous melanoma with BT ≤ 1 mm was signifi-
cantly predictive of metastasis in corresponding sentinel 
lymph node. The greater probability of recurrence with 
increasing BT from T1 to T4 and MR > 2 mitoses/mm2 is 
reported in Fig. 1.
In our study, NM was associated with a significant 
higher risk of recurrence in the univariate analysis but 
the association became not significant in the multi-
variate analysis. By contrast, Faut et  al. [20] found that 
SLNB-negative patients with NM had a significant higher 
recurrence rate in the multivariate analysis (HR 1.82, 
p  =  0.028). However, in our study, the HR was similar 
(1.62) but with a higher CI, resulting in a not significant p 
value. In addition, in Faut et al. [20] study, the significant 
association between NM and higher risk of recurrence 
was found solely in SLNB-negative and not in SLNB-
positive patients. The differences between the two studies 
could depend on the different sample size of both NMs 
and SSMs.
O’ Connel et  al. [21] have also reported a significant 
association between NM subtype and melanoma recur-
rence in patients with negative SLNB. However, in this 
latter study only SLNB- negative patients were included, 
while our series comprised both SLNB negative and posi-
tive patients [21].
In addition, and consistently with our results, other 
Authors found that NM was not significantly associated 
Fig. 1 Probability of recurrence according to thickness (mm) (a) and mitotic rate (n./mm2) (b) in 214 cutaneous melanoma patients
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with higher risk recurrence in the multivariate analy-
sis [22]. Although SSM has been found to have a better 
prognosis than NM, after adjusting for BT, a significant 
difference between two subtypes was not found [8]. Poor 
prognosis of NM could depend on a greater BT, as a con-
sequence of a delayed diagnosis and not due to an intrin-
sic malignant effect of NM.
In our study, a significant association between ulceration 
and increased risk of recurrence was observed only in the 
univariate but not in the multivariate analysis, in agree-
ment with previous studies that did not show an inde-
pendent significant effect of ulceration on prognosis [17].
In addition, we did not find a statistically signifi-
cant correlation between regression and recurrence in 
the univariate analysis. According to Tas et  al. [23], the 
presence of histological regression plays no significant 
prognostic role in melanoma patients. However, the 
meta-analysis of 10 studies proposed that the regression 
can be considered a protective factor, probably depend-
ing on early activation of the host immune system against 
melanoma [24]. The prognostic value of histologic regres-
sion in melanoma remains controversial possibly due to 
lack of a standardized definition and objective criteria for 
histopathological classification of regression-associated 
parameters.
In our study, TIL response was not significantly associ-
ated with recurrence in the univariate analysis. In previ-
ous studies, TIL response was reported as an important 
independent prognostic indicator and the absence of 
TIL was considered as an independent predictor of SNL 
metastasis in melanoma [25].
We cannot exclude that the limited sample size, the 
participation of numerous centers in absence of lack of 
central histopathology review, as well as the relative 
short follow-up may account for this negative result. In 
multicentric studies, improved standardization in den-
sity and distribution of TILs is essential before the bio-
logic and prognostic significance of histologic parameters 
related to immunity such as regression and TILs can be 
recognized.
Unfortunately, the limited series of cases in our study 
did not allow to rule out that NM could represent an 
independent prognostic factor.
Conclusions
In summary, we herein showed that NM subtype was sig-
nificantly associated with higher BT and MR scores. The 
NM subtype per se was not a prognostic factor, since it 
did not significantly affect the melanoma recurrence rate; 
the risk of melanoma recurrence was instead increased 
by higher BT, MR  >  2/mm2, and SNLB positivity. Our 
study limitations did not allow drawing firm conclusions 
on the prognostic role of the NM subtype.
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